Optional antiviral agents for the 2019 novel coronavirus and the liver injury
10.3760/cma.j.cn115673-20200214-00034
- VernacularTitle: 可能用于新型冠状病毒肺炎治疗的抗病毒药物及肝损伤
- Author:
Ping YANG
1
;
Kaijin XU
2
;
Limin KONG
1
;
Na CHEN
1
;
Saiping JIANG
1
;
Xiaoyang LU
1
Author Information
1. Pharmacy Department, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003
2. Department of Infectious Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003
- Publication Type:Journal Article
- Keywords:
2019-nCov;
Antiviral agents;
Liver damage
- From:
Chinese Journal of Clinical Infectious Diseases
2020;13(0):E011-E011
- CountryChina
- Language:Chinese
-
Abstract:
The most important treatment of anti 2019 novel coronavirus is antiviral and supportive treatment. Currently, the anti novel coronavirus drugs in clinical trials include broad-spectrum antiviral drugs (Alpha interferon and Ribavirin), hemagglutinin inhibitors (Arbidol), human immunodeficiency virus protease inhibitors (Lopinavir/Ritonavir and Darunavir/Cobicistat), nucleoside analogues (Favipiravir and Remdesivir) and antimalarial drug (chloroquine), however, some patients suffered from liver damage during the actual usage. This article reviews the research on liver damage associated with anti novel coronavirus drugs, aiming at promoting the rational, safe and effective use of anti novel coronavirus drugs.
